Philippines
Industry
BMI View: While the approval of Roche 's Avastin (bevacizumab) as a first-line treatment for ovarian cancer in the Philippines is a positive decision that will moderate the burden...
2011-10-28Industry
BMI View: The medical device market of the Philippines represents a moderate opportunity for foreign manufacturers. The key drivers of growth are government investments in healthcare...
2011-05-12Industry
BMI Core View: Drugmakers will increasingly use differential pricing in emerging markets. Pharmaceutical companies generally price their patented medicines at the maximum the market...
2011-01-26Economy
Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer...
2010-09-28Industry
Asia Pacific's respect for intellectual property rights with regard to medicine has improved marginally over the past 12 months, according to the Pharmaceutical Research and Manufacturers...
2010-03-09Industry
BMI is maintaining its forecast for the Philippines pharmaceutical market despite another round of medicine price cuts. The Department of Health expects the lower prices of 97 preparations...
2010-03-02Industry
In a bid to boost drug sales in certain emerging markets, multinational drugmaker Sanofi-Aventis has cut the prices of some of its drugs by as much as 50% in the Philippines and Indonesia....
2010-01-14Industry
Bureaucracy and a lack of funding are hampering the implementation of the Universally Accessible Cheaper and Quality Medicines Act in the Philippines. Only 21 pharmaceuticals have...
2009-12-23




